Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) dropped 2.1% on Tuesday . The company traded as low as $1.41 and last traded at $1.41. Approximately 62,343 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 1,897,795 shares. The stock had previously closed at $1.44.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on Adaptimmune Therapeutics in a report on Friday, December 29th. They set a “hold” rating for the company.
Read Our Latest Stock Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Price Performance
Hedge Funds Weigh In On Adaptimmune Therapeutics
Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in shares of Adaptimmune Therapeutics during the first quarter worth $91,000. BlackRock Inc. grew its position in shares of Adaptimmune Therapeutics by 13.7% in the 1st quarter. BlackRock Inc. now owns 1,330,839 shares of the biotechnology company’s stock valued at $2,742,000 after buying an additional 160,146 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Adaptimmune Therapeutics by 124.4% in the first quarter. Renaissance Technologies LLC now owns 959,703 shares of the biotechnology company’s stock valued at $1,977,000 after buying an additional 532,016 shares during the period. State Street Corp raised its position in shares of Adaptimmune Therapeutics by 4.2% during the first quarter. State Street Corp now owns 640,620 shares of the biotechnology company’s stock worth $1,320,000 after acquiring an additional 25,627 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Adaptimmune Therapeutics by 16.7% in the first quarter. Goldman Sachs Group Inc. now owns 359,919 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 51,408 shares during the period. 31.37% of the stock is currently owned by institutional investors.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Recommended Stories
- Five stocks we like better than Adaptimmune Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Consumer Discretionary Stocks Explained
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- Stock Dividend Cuts Happen Are You Ready?
- Cintas or UniFirst: Investors Win Either Way
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.